Clinical Benefit of Delamanid (OPC-67683) in the Treatment of Multidrug-Resistant Tuberculosis Patients in China (original) (raw)

References

  1. Wright, A., Zignol, M., Van Deun, A., et al. (2009). Epidemiology of antituberculosis drug resistance 2002–07: An updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet, 373, 1861–1873.
    Article PubMed Google Scholar
  2. Kim, D. H., Kim, H. J., Park, S.-K., et al. (2008). Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis. American Journal of Respiratory and Critical Care Medicine, 178, 1075–1082.
    Article PubMed CAS Google Scholar
  3. Kwon, Y. S., Kim, Y. H., Suh, G. Y., et al. (2008). Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Clinical Infectious Diseases, 47, 496–502.
    Article PubMed Google Scholar
  4. Mitnick, C., Castro, K., Harrington, M., Sacks, L., & Burman, W. (2007). Randomized trials to optimize treatment of multidrug-resistant tuberculosis. PLoS Medicine, 4, e292.
    Article PubMed Google Scholar
  5. World Health Organization. (2008). _Global tuberculosis control: Surveillance, planning, financin_g. WHO report 2008. WHO/HTM/TB/2008.393. Geneva, Switzerland.
  6. World Health Organization. (2010). Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. WHO/HTM/TB/2010.3.
  7. Stop TB Partnership and World Health Organization. (2006). Global plan to stop TB 2006–2015. WHO/HTM/STB/2006.35 Geneva: World Health Organization.
  8. World Health Organization. (2006). Addressing the threat of tuberculosis caused by extensively drug-resistant Mycobacterium tuberculosis. Weekly Epidemiology Record, 81, 386–390.
    Google Scholar
  9. Matsumoto, M., Hiroyuki, H., Tatsuo, T., et al. (2006). OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. Public Library Science Medicine, 3, e466.
    Google Scholar
  10. Matsumoto M. (2003). In vitro activities of OPC-67683 and reference compounds against Mycobacterium tuberculosis standard strains and Mycobacterium bovis strains. Otsuka Study No. 019064.
  11. Matsumoto M. (2003). In vitro activities of OPC-67683 and reference compounds against clinically isolated Mycobacterium tuberculosis. Otsuka Study No. 019196, Otsuka Report No. 019196, Otsuka Report No. 015366.
  12. Matsumoto M. (2005). Inhibitory activity of OPC-67683 against mycolic acid synthesis in Mycobacterium bovis BCG. Otsuka Study No. 021327, Otsuka Report No. 017300.
  13. Gler, M. T., Skripconoka, V., Sanchez-Garavito, E., et al. (2012). Delamanid for patients with multi-drug resistant pulmonary tuberculosis. The New England Journal of Medicine, 366, 1–10.
    Article Google Scholar
  14. World Health Organization (2008). Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis: Emergency Update 2008. WHO/HTM/TB/2008.402.
  15. World Health Organization. (2010). Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. WHO/HTM/TB/2010.3.
  16. Schecter, G. F., Scott, C., True, L., Raftery, A., Flood, J., & Mase, S. (2010). Linezolid in the treatment of multidrug-resistant tuberculosis. Clinical Infectious Diseases, 50, 49–55.
    Article PubMed CAS Google Scholar
  17. Chan, E., & Iseman, M. (2008). Multidrug-resistant and extensively drug-resistant tuberculosis: A review. Current Opinion in Infectious Diseases, 21, 587–595.
    Article PubMed CAS Google Scholar
  18. Orenstein, E. W., Basu, S., Shah, N. S., et al. (2009). Treatment outcomes among patients with multidrug-resistant tuberculosis: Systematic review and meta-analysis. Lancet Infectious Diseases, 9, 153–161.
    Article PubMed Google Scholar
  19. Johnston, J. C., Shahidi, N. C., Sadatsafavi, M., et al. (2009). Treatment outcomes of multidrug-resistant tuberculosis: A systematic review and meta-analysis. PLoS ONE, 4(9), e6914.
    Article PubMed Google Scholar
  20. Mitnick, C., Bayona, J., Palacios, E., et al. (2003). Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. The New England Journal of Medicine, 348, 119–128.
    Article PubMed Google Scholar
  21. Leimane, V., Reikstina, V., Holtz, T., et al. (2005). Clinical outcomes of individualized treatment of multidrug-resistant tuberculosis in Latvia: A retrospective cohort study. Lancet, 365, 318–326.
    PubMed Google Scholar
  22. Caminaro, J. A. (2006). Treatment of multidrug-resistant tuberculosis: Evidence and controversies. International Journal of Tuberculosis and Lung Diseases, 10, 829–837.
    Google Scholar
  23. Chan, E. D., Laurel, V., Strand, M. J., et al. (2004). Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. American Journal of Critical Care Medicine, 169, 1103–1109.
    Article Google Scholar
  24. WHO. (2006). Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: WHO.

Download references